Lakefront Biotherapeutics NV business relationships
Companies named in Lakefront Biotherapeutics NV’s 20-F filed 2026-03-26, and public companies whose annual reports name Lakefront Biotherapeutics NV. Each link shows the sentence it came from. Scores are Engagemii’s AI visibility scores.
- AEO visibility
- 4.7 / 10
- AI naming
- 21 / 100 Top 1% in its category
- Agent readiness
- 40 / 100
- AI adoption
- 0 / 100
Named in Lakefront Biotherapeutics NV’s annual report 6
“All commercial economics on filgotinib in Europe transferred to us as of January 1, 2022, subject to payment of tiered royalties of 8 to 15% of net sales in Europe to Gilead, starting in 2024 .” SEC filing
“For the year ended December 31, 2025 we recognized in revenue € 12.2 million of royalties from Gilead on filgotinib.” SEC filing
“Under the agreement as revised in 2019, we and Gilead would co-commercialize filgotinib in France, Germany, Italy, Spain and the United Kingdom and retain the 50/50 profit share in these countries that was part of the original filgotinib license agreement.” SEC filing
“The revenues from our collaboration partner Gilead represented 97 % of our total net revenues from continuing operations in 2025 ( 87 % in 2024, nearly 100 % in 2023).” SEC filing
“In addition, we are heavily dependent on Gilead for the commercialization of filgotinib.” SEC filing
“Effective January 31, 2024, following the closing of the transaction between us and Alfasigma S.p.A. to transfer the Jyseleca® business to Alfasigma S.p.A., we assigned our rights and obligations under the filgotinib collaboration to Alfasigma S.p.A., except for our right to receive royalties from G...” SEC filing
Links are read automatically from SEC annual reports (10-K, 20-F, 40-F). In a hand check of random links, about 8 in 10 were real business relationships, so every link carries its source sentence.